BioCentury | Aug 21, 2020
Management Tracks

IRRAS’s Wiklund has passed away

...the boards of more than a half a dozen life companies and chaired several, including Pharmalink AB...
BioCentury | Aug 15, 2017
Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

...NASDAQ:MACK) named Jean Franchi CFO. She was CFO at Dimension Therapeutics Inc. (NASDAQ:DMTX). Renal company Pharmalink AB...
BioCentury | Oct 5, 2015
Financial News

Pharmalink completes venture financing

Pharmalink AB , Stockholm, Sweden Business: Renal, Transplant Date completed: 2015-10-01 Type: Venture financing Raised: SEK100 million ($11.9 million) Investors: Investinor A/S; Industrifonden ; existing investors WIR Staff...
BioCentury | Apr 27, 2015
Company News

Synartro, Pharmalink deal

...technology. Pharmalink plans to develop the product to treat osteoarthritis. Synartro AB , Uppsala, Sweden Pharmalink AB...
BioCentury | Apr 20, 2015
Clinical News

Nefecon: Phase IIb data

...9 months vs. placebo (p=0.0066). Patients received placebo or once-daily 8 or 16 mg Nefecon. Pharmalink...
...it will meet with FDA and EMA after reporting final Phase IIb data in 3Q15. Pharmalink...
...Nefecon in the indication (see BioCentury, Dec. 19, 2011). Archimedes Pharma Ltd. , Reading, U.K. Pharmalink AB...
BioCentury | Apr 15, 2015
Clinical News

Pharmalink's Nefecon meets nephropathy endpoint

...European trial enrolled over 150 IgA nephropathy patients with persistent proteinuria despite optimized standard-of-care therapy. Pharmalink...
BioCentury | Oct 20, 2014
Company News

Pharmalink board of directors update

Pharmalink AB , Stockholm, Sweden Business: Renal, Transplant Appointed: Bengt Julander, a director, as chairman; he succeeds Anders Wiklund, who remains a senior advisor WIR Staff...
BioCentury | Mar 24, 2014
Company News

Oxford Pharmascience Group management update

...Drug delivery Hired: Liz King as director of R&D, formerly associate director of operations at Pharmalink...
BioCentury | Jan 20, 2014
Clinical News

Nefecon: Completed Phase IIb enrollment

...9 months. The company plans to seek a commercial partner for Nefecon in all territories. Pharmalink...
...Orphan Drug designation for the indication in the U.S. Archimedes Pharma Ltd. , Reading, U.K. Pharmalink AB...
BioCentury | Nov 4, 2013
Clinical News

Busulipo regulatory update

...to evaluate the product next year and partner it for territories outside the Nordic region. Pharmalink AB...
Items per page:
1 - 10 of 29
BioCentury | Aug 21, 2020
Management Tracks

IRRAS’s Wiklund has passed away

...the boards of more than a half a dozen life companies and chaired several, including Pharmalink AB...
BioCentury | Aug 15, 2017
Company News

Management tracks: Cerecor, Allakos, Epizyme, Merrimack

...NASDAQ:MACK) named Jean Franchi CFO. She was CFO at Dimension Therapeutics Inc. (NASDAQ:DMTX). Renal company Pharmalink AB...
BioCentury | Oct 5, 2015
Financial News

Pharmalink completes venture financing

Pharmalink AB , Stockholm, Sweden Business: Renal, Transplant Date completed: 2015-10-01 Type: Venture financing Raised: SEK100 million ($11.9 million) Investors: Investinor A/S; Industrifonden ; existing investors WIR Staff...
BioCentury | Apr 27, 2015
Company News

Synartro, Pharmalink deal

...technology. Pharmalink plans to develop the product to treat osteoarthritis. Synartro AB , Uppsala, Sweden Pharmalink AB...
BioCentury | Apr 20, 2015
Clinical News

Nefecon: Phase IIb data

...9 months vs. placebo (p=0.0066). Patients received placebo or once-daily 8 or 16 mg Nefecon. Pharmalink...
...it will meet with FDA and EMA after reporting final Phase IIb data in 3Q15. Pharmalink...
...Nefecon in the indication (see BioCentury, Dec. 19, 2011). Archimedes Pharma Ltd. , Reading, U.K. Pharmalink AB...
BioCentury | Apr 15, 2015
Clinical News

Pharmalink's Nefecon meets nephropathy endpoint

...European trial enrolled over 150 IgA nephropathy patients with persistent proteinuria despite optimized standard-of-care therapy. Pharmalink...
BioCentury | Oct 20, 2014
Company News

Pharmalink board of directors update

Pharmalink AB , Stockholm, Sweden Business: Renal, Transplant Appointed: Bengt Julander, a director, as chairman; he succeeds Anders Wiklund, who remains a senior advisor WIR Staff...
BioCentury | Mar 24, 2014
Company News

Oxford Pharmascience Group management update

...Drug delivery Hired: Liz King as director of R&D, formerly associate director of operations at Pharmalink...
BioCentury | Jan 20, 2014
Clinical News

Nefecon: Completed Phase IIb enrollment

...9 months. The company plans to seek a commercial partner for Nefecon in all territories. Pharmalink...
...Orphan Drug designation for the indication in the U.S. Archimedes Pharma Ltd. , Reading, U.K. Pharmalink AB...
BioCentury | Nov 4, 2013
Clinical News

Busulipo regulatory update

...to evaluate the product next year and partner it for territories outside the Nordic region. Pharmalink AB...
Items per page:
1 - 10 of 29